

Graham S Cooke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/705954/publications.pdf>

Version: 2024-02-01

204
papers

18,474
citations

28274
55
h-index

15266
126
g-index

255
all docs

255
docs citations

255
times ranked

32026
citing authors

#	ARTICLE	IF	CITATIONS
1	The Global Burden of Cancer 2013. JAMA Oncology, 2015, 1, 505.	7.1	2,269
2	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990â€“2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	13.7	1,544
3	Global distribution and prevalence of hepatitis C virus genotypes. Hepatology, 2015, 61, 77-87.	7.3	1,293
4	The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet, The, 2016, 388, 1081-1088.	13.7	1,080
5	Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clinical Infectious Diseases, 2020, 71, 2459-2468.	5.8	1,006
6	Oral versus Intravenous Antibiotics for Bone and Joint Infection. New England Journal of Medicine, 2019, 380, 425-436.	27.0	548
7	Genetics of susceptibility to human infectious disease. Nature Reviews Genetics, 2001, 2, 967-977.	16.3	447
8	Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe, The, 2020, 1, e245-e253.	7.3	441
9	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	13.7	413
10	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2019, 4, 135-184.	8.1	370
11	Technologies for global health. Lancet, The, 2012, 380, 507-535.	13.7	311
12	The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut, 2016, 65, 1369-1376.	12.1	267
13	Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2016, 62, 683-694.	5.8	262
14	Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clinical Infectious Diseases, 2015, 61, 730-740.	5.8	229
15	Association between tuberculosis and a polymorphic NFÎB binding site in the interferon Î³ gene. Lancet, The, 2003, 361, 1871-1872.	13.7	216
16	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe, The, 2021, 2, e354-e365.	7.3	216
17	Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet, The, 2019, 393, 1319-1329.	13.7	212
18	Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nature Communications, 2022, 13, 1957.	12.8	198

#	ARTICLE	IF	CITATIONS
19	Localized spatial clustering of HIV infections in a widely disseminated rural South African epidemic. <i>International Journal of Epidemiology</i> , 2009, 38, 1008-1016.	1.9	173
20	SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. <i>Nature Communications</i> , 2021, 12, 905.	12.8	168
21	Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 449-456.	9.1	164
22	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 349-359.	10.7	161
23	Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. <i>Bulletin of the World Health Organization</i> , 2009, 87, 754-762.	3.3	145
24	Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. <i>Thorax</i> , 2020, 75, 1082-1088.	5.6	133
25	Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. <i>Nature Genetics</i> , 2017, 49, 666-673.	21.4	129
26	A prenylated dsRNA sensor protects against severe COVID-19. <i>Science</i> , 2021, 374, eabj3624.	12.6	124
27	Retention in HIV Care for Individuals Not Yet Eligible for Antiretroviral Therapy: Rural KwaZulu-Natal, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e79-e86.	2.1	122
28	Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? <i>Epidemiological and Modeling Insights</i> . <i>Clinical Infectious Diseases</i> , 2016, 62, 1072-1080.	5.8	122
29	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 699-711.	10.7	122
30	Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 284-293.	3.0	116
31	Polymorphism within the Interferon- γ /Receptor Complex Is Associated with Pulmonary Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 339-343.	5.6	111
32	Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. <i>Science</i> , 2021, 374, eabl9551.	12.6	111
33	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. <i>Lancet</i> , The, 2021, 398, 223-237.	13.7	110
34	Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 819-824.	9.1	107
35	Encouraging AWARe-ness and discouraging inappropriate antibiotic use—the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1278-1280.	9.1	106
36	Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes?. <i>Bulletin of the World Health Organization</i> , 2010, 88, 593-600.	3.3	104

#	ARTICLE	IF	CITATIONS
37	Viral hepatitis and the global burden of Disease: a need to regroup . Journal of Viral Hepatitis, 2013, 20, 600-601.	2.0	104
38	Impact of point-of-care CD4 testing on linkage to HIV care: a systematic review. Journal of the International AIDS Society, 2014, 17, 18809.	3.0	104
39	Rapid increase in Omicron infections in England during December 2021: REACT-1 study. Science, 2022, 375, 1406-1411.	12.6	99
40	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01 _B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. Journal of Infectious Diseases, 2016, 214, 772-781.	4.0	96
41	Risk of Tuberculosis Infection and Disease for Health Care Workers: An Updated Meta-Analysis. Open Forum Infectious Diseases, 2017, 4, ofx137.	0.9	95
42	Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nature Communications, 2022, 13, 907.	12.8	94
43	REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. Wellcome Open Research, 2020, 5, 200.	1.8	93
44	Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. Lancet Microbe, The, 2020, 1, e300-e307.	7.3	92
45	Resurgence of SARS-CoV-2: Detection by community viral surveillance. Science, 2021, 372, 990-995.	12.6	91
46	Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. Lancet Regional Health - Europe, The, 2021, 4, 100098.	5.6	91
47	Mapping of a Novel Susceptibility Locus Suggests a Role for MC3R and CTSZ in Human Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 203-207.	5.6	83
48	Clinical Characteristics and Predictors of Outcomes of Hospitalized Patients With Coronavirus Disease 2019 in a Multiethnic London National Health Service Trust: A Retrospective Cohort Study. Clinical Infectious Diseases, 2021, 73, e4047-e4057.	5.8	81
49	Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. Journal of Antimicrobial Chemotherapy, 2011, 66, 1815-1820.	3.0	80
50	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine, the, 2021, 9, 773-785.	10.7	78
51	Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England. Science, 2022, 376, .	12.6	78
52	Predictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million people. PLoS Medicine, 2021, 18, e1003777.	8.4	72
53	Population uptake of antiretroviral treatment through primary care in rural South Africa. BMC Public Health, 2010, 10, 585.	2.9	71
54	Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDS. Clinical Infectious Diseases, 2012, 54, 1465-1472.	5.8	71

#	ARTICLE	IF	CITATIONS
55	Wearable sensors to improve detection of patient deterioration. Expert Review of Medical Devices, 2019, 16, 145-154.	2.8	70
56	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nature Communications, 2021, 12, 4450.	12.8	67
57	COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. Infection, 2021, 49, 889-905.	4.7	62
58	Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapy. Tropical Medicine and International Health, 2014, 19, 501-513.	2.3	60
59	Hepatitis C can be cured globally, but at what cost?. Science, 2014, 345, 141-142.	12.6	60
60	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatology, The, 2021, 3, e498-e506.	3.9	58
61	Low levels of HIV test coverage in clinical settings in the UK: a systematic review of adherence to 2008 guidelines. Sexually Transmitted Infections, 2014, 90, 119-124.	1.9	57
62	Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bulletin of the World Health Organization, 2012, 90, 540-550.	3.3	56
63	SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. BMJ, The, 2021, 372, n423.	6.0	56
64	Usability and Acceptability of Home-based Self-testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies for Population Surveillance. Clinical Infectious Diseases, 2021, 72, e384-e393.	5.8	55
65	REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. Wellcome Open Research, 2020, 5, 200.	1.8	55
66	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clinical Infectious Diseases, 2019, 69, 2218-2227.	5.8	52
67	Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology, 2015, 61, 1174-1182.	7.3	51
68	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. Npj Vaccines, 2018, 3, 49.	6.0	51
69	Clinical utility of existing and second-generation interferon-Î³ release assays for diagnostic evaluation of tuberculosis: an observational cohort study. Lancet Infectious Diseases, The, 2019, 19, 193-202.	9.1	47
70	Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom?. Clinical Infectious Diseases, 2021, 72, 233-238.	5.8	45
71	The tuberculosis challenge in a rural South African HIV programme. BMC Infectious Diseases, 2010, 10, 23.	2.9	44
72	A Comparison between Two Strategies for Monitoring Hepatic Function during Antituberculous Therapy. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 653-659.	5.6	44

#	ARTICLE	IF	CITATIONS
73	Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study. PLoS ONE, 2008, 3, e3173.	2.5	42
74	Digital Alerting and Outcomes in Patients With Sepsis: Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 2019, 21, e15166.	4.3	41
75	SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys. Lancet Respiratory Medicine, 2022, 10, 355-366.	10.7	39
76	Association of Fcγ receptor 1a (CD32) polymorphism with severe malaria in West Africa. American Journal of Tropical Medicine and Hygiene, 2003, 69, 565-8.	1.4	39
77	Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. World Journal of Gastroenterology, 2013, 19, 1602.	3.3	38
78	Impact of Point-of-Care Xpert MTB/RIF on Tuberculosis Treatment Initiation. A Cluster-randomized Trial. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 901-910.	5.6	37
79	Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	37
80	Namylumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Respiratory Medicine, 2022, 10, 255-266.	10.7	32
81	PD-1 Expression and Cytokine Secretion Profiles of Mycobacterium tuberculosis-Specific CD4+ T-Cell Subsets; Potential Correlates of Containment in HIV-TB Co-Infection. PLoS ONE, 2016, 11, e0146905.	2.5	31
82	Treatment Outcomes of Treatment-Naïve Hepatitis C Patients Co-Infected with HIV: A Systematic Review and Meta-Analysis of Observational Cohorts. PLoS ONE, 2013, 8, e55373.	2.5	30
83	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. Journal of Virus Eradication, 2015, 1, 103-110.	0.5	28
84	Strength of recommendations in WHO guidelines using GRADE was associated with uptake in national policy. Journal of Clinical Epidemiology, 2015, 68, 703-707.	5.0	28
85	A Polymorphism That Reduces RANTES Expression Is Associated with Protection from Death in HIV-Seropositive Ugandans with Advanced Disease. Journal of Infectious Diseases, 2006, 194, 666-669.	4.0	27
86	Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT. Health Technology Assessment, 2019, 23, 1-92.	2.8	27
87	Response to Mallet et al., "Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients". Aids, 2007, 21, 1494-1495.	2.2	25
88	Treatment of Cryptococcal Meningitis in KwaZulu-Natal, South Africa. PLoS ONE, 2010, 5, e8630.	2.5	24
89	Tracking the progress of HIV: the impact of point-of-care tests on antiretroviral therapy. Clinical Epidemiology, 2013, 5, 387.	3.0	24
90	Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis. The Lancet Global Health, 2019, 7, e1189-e1196.	6.3	24

#	ARTICLE	IF	CITATIONS
91	Shortâ€Duration Panâ€Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection. Hepatology, 2020, 72, 7-18.	7.3	24
92	Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?. The Lancet Gastroenterology and Hepatology, 2020, 5, 948-953.	8.1	24
93	Treatment for hepatitis B. BMJ: British Medical Journal, 2010, 340, b5429-b5429.	2.3	24
94	Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. Journal of Infection, 2019, 79, 503-512.	3.3	23
95	International Spread of MDR TB from Tugela Ferry, South Africa. Emerging Infectious Diseases, 2011, 17, 2035-7.	4.3	22
96	Evaluation of Tuberculosis Diagnostics: Establishing an Evidence Base Around the Public Health Impact. Journal of Infectious Diseases, 2011, 204, S1187-S1195.	4.0	21
97	Evaluating a digital sepsis alert in a London multisite hospital network: a natural experiment using electronic health record data. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 274-283.	4.4	21
98	Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Research, 2019, 4, 132.	1.8	21
99	Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation. Aids, 2019, 33, 805-814.	2.2	20
100	Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. The Lancet Digital Health, 2022, 4, e220-e234.	12.3	20
101	Estimated generic prices for novel treatments for drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw522.	3.0	19
102	Global surveillance, research, and collaboration needed to improve understanding and management of long COVID. Lancet, The, 2021, 398, 2057-2059.	13.7	19
103	Can Hepatitis C Virus Antigen Testing Replace Ribonucleic Acid Polymearse Chain Reaction Analysis for Detecting Hepatitis C Virus? A Systematic Review. Open Forum Infectious Diseases, 2017, 4, ofw252.	0.9	18
104	Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study. Lancet Infectious Diseases, The, 2021, 21, 1429-1440.	9.1	18
105	Impact on and use of an inner-city London Infectious Diseases Department by international migrants: a questionnaire survey. BMC Health Services Research, 2007, 7, 113.	2.2	17
106	Changes in Emergency Department Activity and the First COVID-19 Lockdown: A Cross-sectional Study. Western Journal of Emergency Medicine, 2021, 22, 603-607.	1.1	17
107	Discovery and validation of a three-gene signature to distinguish COVID-19 and other viral infections in emergency infectious disease presentations: a case-control and observational cohort study. Lancet Microbe, The, 2021, 2, e594-e603.	7.3	17
108	Transmission of hepatitis C virus in HIVâ€positive and PrEPâ€using MSM in England. Journal of Viral Hepatitis, 2020, 27, 721-730.	2.0	16

#	ARTICLE	IF	CITATIONS
109	Association between intrahospital transfer and hospital-acquired infection in the elderly: a retrospective caseâ€“control study in a UK hospital network. <i>BMJ Quality and Safety</i> , 2021, 30, 457-466.	3.7	16
110	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. <i>Journal of Virus Eradication</i> , 2015, 1, 103-10.	0.5	16
111	Hepatitis B treatment in resource poor settings: time for action. <i>Tropical Medicine and International Health</i> , 2009, 15, 2-4.	2.3	15
112	Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008â€“2014. <i>Journal of Infection</i> , 2017, 74, 260-271.	3.3	15
113	The impact of the COVID-19 pandemic on patterns of attendance at emergency departments in two large London hospitals: an observational study. <i>BMC Health Services Research</i> , 2021, 21, 1008.	2.2	15
114	Appropriately smoothing prevalence data to inform estimates of growth rate and reproduction number. <i>Epidemics</i> , 2022, 40, 100604.	3.0	15
115	Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. <i>PLoS ONE</i> , 2019, 14, e0212734.	2.5	14
116	National Institute for Health Research Health Informatics Collaborative: development of a pipeline to collate electronic clinical data for viral hepatitis research. <i>BMJ Health and Care Informatics</i> , 2020, 27, e100145.	3.0	14
117	A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination. <i>Seminars in Liver Disease</i> , 2022, 42, 159-172.	3.6	14
118	Cluster of Falciparum Malaria Cases in UK Airport. <i>Emerging Infectious Diseases</i> , 2008, 14, 1284-1286.	4.3	13
119	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2019, 22, 693-703.	0.3	13
120	Machine learning to support visual auditing of home-based lateral flow immunoassay self-test results for SARS-CoV-2 antibodies. <i>Communications Medicine</i> , 2022, 2, .	4.2	13
121	Fatal Nosocomial MDR TB Identified through Routine Genetic Analysis and Whole-Genome Sequencing. <i>Emerging Infectious Diseases</i> , 2015, 21, 1082-1084.	4.3	12
122	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. <i>PLoS ONE</i> , 2020, 15, e0235715.	2.5	12
123	2019 Community-acquired Pneumonia Treatment Guidelines: There Is a Need for a Change toward More Parsimonious Antibiotic Use. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1315-1316.	5.6	12
124	Acceptability, Usability, and Performance of Lateral Flow Immunoassay Tests for Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: REACT-2 Study of Self-Testing in Nonhealthcare Key Workers. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab496.	0.9	12
125	Antiviral metabolite 3â€²-deoxy-3â€²,4â€²-didehydro-cytidine is detectable in serum and identifies acute viral infections including COVID-19. <i>Med</i> , 2022, 3, 204-215.e6.	4.4	12
126	Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO. <i>BMJ Open</i> , 2022, 12, e053349.	1.9	12

#	ARTICLE	IF	CITATIONS
127	Differences in antigen-specific CD4+ responses to opportunistic infections in HIV infection. <i>Immunity, Inflammation and Disease</i> , 2015, 3, 141-153.	2.7	11
128	Predictors of recurrence, early treatment failure and death from <i>Staphylococcus aureus</i> bacteraemia: Observational analyses within the ARREST trial. <i>Journal of Infection</i> , 2019, 79, 332-340.	3.3	11
129	Responses to Quadrivalent Influenza Vaccine Reveal Distinct Circulating CD4+CXCR5+ T Cell Subsets in Men Living with HIV. <i>Scientific Reports</i> , 2019, 9, 15650.	3.3	11
130	Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa. <i>Journal of AIDS & Clinical Research</i> , 2013, 01, .	0.5	11
131	F-18 FDG PET in the Diagnosis and Monitoring of <i>Salmonella</i> Vertebral Osteomyelitis: A Comparison With MRI. <i>Clinical Nuclear Medicine</i> , 2006, 31, 437-440.	1.3	10
132	Need for Timely Paediatric HIV Treatment within Primary Health Care in Rural South Africa. <i>PLoS ONE</i> , 2009, 4, e7101.	2.5	10
133	Acute renal failure due to immune reconstitution inflammatory interstitial nephritis in an HIV-positive patient. <i>Aids</i> , 2010, 24, 1788-1790.	2.2	10
134	Short-Term Wearable Sensors for In-Hospital Medical and Surgical Patients: Mixed Methods Analysis of Patient Perspectives. <i>JMIR Perioperative Medicine</i> , 2021, 4, e18836.	1.0	10
135	HIV and hepatitis B co-infection in Africa. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 210-211.	9.1	9
136	The under-representation of BAME patients in the COVID-19 Recovery trial at a major London NHS Trust. <i>Journal of Infection</i> , 2021, 82, 84-123.	3.3	9
137	Spleen stiffness measurements using point shear wave elastography detects noncirrhotic portal hypertension in human immunodeficiency virus. <i>Medicine (United States)</i> , 2019, 98, e17961.	1.0	8
138	A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK. <i>Journal of Infection</i> , 2020, 80, 38-41.	3.3	8
139	Progress towards antibiotic use targets in eight high-income countries. <i>Bulletin of the World Health Organization</i> , 2021, 99, 550-561.	3.3	8
140	Rational use of SARS-CoV-2 polymerase chain reaction tests within institutions caring for the vulnerable. <i>F1000Research</i> , 2020, 9, 671.	1.6	8
141	Might ART Adherence Estimates Be Improved by Combining Biomarker and Self-Report Data?. <i>PLoS ONE</i> , 2016, 11, e0167852.	2.5	8
142	Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. <i>Journal of Virological Methods</i> , 2022, 302, 114475.	2.1	8
143	Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study. <i>EClinicalMedicine</i> , 2022, 48, 101419.	7.1	8
144	Comparison of screening strategies to improve the diagnosis of latent tuberculosis infection in the HIV-positive population: a cohort study. <i>BMJ Open</i> , 2012, 2, e000762.	1.9	7

#	ARTICLE	IF	CITATIONS
145	Impact of virus subtype and host <i>IFNL4</i> genotype on large-scale RNA structure formation in the genome of hepatitis C virus. <i>Rna</i> , 2020, 26, 1541-1556.	3.5	7
146	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. Wellcome Open Research, 2021, 6, 93.	1.8	7
147	Characterising the persistence of RT-PCR positivity and incidence in a community survey of SARS-CoV-2. Wellcome Open Research, 0, 7, 102.	1.8	7
148	Impact of a novel molecular TB diagnostic system in patients at high risk of TB mortality in rural South Africa (Uchwepheshe): study protocol for a cluster randomised trial. <i>Trials</i> , 2013, 14, 170.	1.6	6
149	High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab267.	0.9	6
150	Cohort study protocol: Bioresource in Adult Infectious Diseases (BioAID). Wellcome Open Research, 2018, 3, 97.	1.8	6
151	A new paradigm evaluating cost per cure of HCV infection in the UK. <i>Hepatology, Medicine and Policy</i> , 2016, 1, 2.	1.7	5
152	Scaling&sup HCV treatment to achieve WHO targets by 2030. <i>Tropical Medicine and International Health</i> , 2017, 22, 372-374.	2.3	5
153	The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam. <i>Trials</i> , 2020, 21, 413.	1.6	5
154	Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China. <i>PLoS ONE</i> , 2021, 16, e0245288.	2.5	5
155	Decentralisation, integration, and task-shifting: tools to accelerate the elimination of hepatitis C. <i>The Lancet Global Health</i> , 2021, 9, e375-e376.	6.3	5
156	Global access to affordable direct oral anticoagulants. <i>Bulletin of the World Health Organization</i> , 2021, 99, 653-660.	3.3	5
157	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. Wellcome Open Research, 0, 6, 358.	1.8	5
158	Deep-Seated Resistance in Relapsed Paratyphoid Fever. <i>Clinical Infectious Diseases</i> , 2006, 42, e92-e94.	5.8	4
159	Diagnostics for resource&limited settings in the era of interferon&free <sc>HCV</sc> therapy. <i>Journal of Viral Hepatitis</i> , 2015, 22, 459-460.	2.0	4
160	HCV and HIV: shared challenges, shared solutions. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 755-756.	9.1	4
161	THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection. <i>Journal of Hepatology</i> , 2019, 70, e231.	3.7	4
162	Launch of the Coalition for Global Hepatitis Elimination: a recommendation of the Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 8-10.	8.1	4

#	ARTICLE	IF	CITATIONS
163	<i>Strongyloides stercoralis</i> infection in HIV-positive men who have sex with men. International Journal of STD and AIDS, 2020, 31, 398-401.	1.1	4
164	The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. Wellcome Open Research, 2019, 4, 129.	1.8	4
165	The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. Wellcome Open Research, 2019, 4, 129.	1.8	4
166	Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-infected patients with mild liver disease. Journal of Viral Hepatitis, 2016, 23, 123-129.	2.0	3
167	Hepatitis in the traveller. Medicine, 2018, 46, 20-23.	0.4	3
168	Reply to Dudoignon et al. Clinical Infectious Diseases, 2021, 72, 906-908.	5.8	3
169	Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility. SSRN Electronic Journal, 0, , .	0.4	3
170	Simple, sensitive, specific self-sampling assay secures SARS-CoV-2 antibody signals in sero-prevalence and post-vaccine studies. Scientific Reports, 2022, 12, 1885.	3.3	3
171	Perceptions on the Use of Wearable Sensors and Continuous Monitoring in Surgical Patients: Interview Study Among Surgical Staff. JMIR Formative Research, 2022, 6, e27866.	1.4	3
172	Seroprevalence of Hepatitis B, C and D in Vietnam: A systematic review and meta-analysis. The Lancet Regional Health - Western Pacific, 2022, 24, 100468.	2.9	3
173	The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype. Aids, 2013, 27, 484-485.	2.2	2
174	A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. Journal of Antimicrobial Chemotherapy, 2015, 70, 1812-5.	3.0	2
175	Do countries have the right policies to eliminate viral hepatitis B and C: a secondary analysis of the Lancet GastroHep viral hepatitis commission. Journal of Hepatology, 2020, 73, S811.	3.7	2
176	Changes in the hospital admission profile of COVID-19 positive patients at a central London trust. Journal of Infection, 2021, 82, 159-198.	3.3	2
177	In vivo negative regulation of SARS-CoV-2 receptor, ACE2, by interferons and its genetic control. Wellcome Open Research, 0, 6, 47.	1.8	2
178	Identification of hepatitis delta superinfection when investigating transaminitis in HIV/hepatitis B virus co-infection. Aids, 2021, 35, 1704-1706.	2.2	2
179	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. Wellcome Open Research, 0, 6, 358.	1.8	2
180	Cohort Profile: The National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) research dataset. International Journal of Epidemiology, 0, , .	1.9	2

#	ARTICLE	IF	CITATIONS
181	Evolution of adult antiretroviral therapy for programmatic delivery in Africa and the potential role for new therapeutic approaches. <i>Therapy: Open Access in Clinical Medicine</i> , 2007, 4, 767-774.	0.2	1
182	Improving the treatment of hepatitis C infection in the UK. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 183-191.	1.8	1
183	Early impact on adult mortality from a government art programme in rural kwazulu-natal. <i>Journal of Infection</i> , 2008, 56, 303-304.	3.3	1
184	Host Genetics and Susceptibility to Infection. , 2011, , 32-39.		1
185	Genotype 4 and the global challenge of hepatitis C treatment. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 3-4.	8.1	1
186	Can routine genetic testing help to end TB transmission?. <i>Thorax</i> , 2016, 71, 681-682.	5.6	1
187	Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2020, 23, 180-190.	0.3	1
188	Interventions to reduce acute hepatitis C virus in HIV-positive MSM. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 1-9.	3.1	1
189	Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease. <i>Journal of Infection</i> , 2020, 81, 647-679.	3.3	1
190	Factors associated with reattendance to emergency services following COVID-19 hospitalization. <i>Journal of Medical Virology</i> , 2021, 93, 1250-1252.	5.0	1
191	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. <i>Wellcome Open Research</i> , 2021, 6, 93.	1.8	1
192	Liver disease: at the heart of public health challenges for Europe in the 21st century. <i>Lancet, The</i> , 2022, 399, 9-10.	13.7	1
193	Engaging with HCV reinfection to advance microelimination. <i>Lancet HIV,the</i> , 2022, 9, e372-e374.	4.7	1
194	Identification of Susceptibility Genes for Tuberculosis in Southern and West Africans Using Family-Based Linkage Analysis and Linkage Disequilibrium Mapping. <i>Clinical Science</i> , 2003, 104, 56P-56P.	0.0	0
195	Jaundice in the traveller. <i>Medicine</i> , 2010, 38, 14-17.	0.4	0
196	Pricing viral hepatitis as part of universal health coverage. <i>The Lancet Global Health</i> , 2019, 7, e1148-e1149.	6.3	0
197	Decline in HCV incidence in HIV positive MSM - progress to HCV micro-elimination in the UK?. <i>Journal of Hepatology</i> , 2020, 73, S32-S33.	3.7	0
198	From stagnation to elimination: tracking hepatitis C elimination policy implementation in Europe in partnership with patient organizations. <i>Journal of Hepatology</i> , 2020, 73, S793-S794.	3.7	0

#	ARTICLE	IF	CITATIONS
199	Cuts to UK official development assistance budget jeopardise global viral hepatitis elimination goals. The Lancet Gastroenterology and Hepatology, 2021, 6, 527-528.	8.1	0
200	Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. Wellcome Open Research, 0, 6, 203.	1.8	0
201	Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-90.	0.7	0
202	Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial. Blood, 2021, 138, 4200-4200.	1.4	0
203	Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. Wellcome Open Research, 0, 6, 203.	1.8	0
204	Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. Wellcome Open Research, 0, 7, 51.	1.8	0